Home › News and Press

News and Press releases

View all News Press releases

Oxcia AB Publishes Year-End Report for 2024

February 21, 2025 · News and Press

OXC-101 has been granted ODD status by the FDA in AML

February 20, 2025 · News and Press

Oxcia appoints Eva Sjökvist Saers as Chairman of the Board

February 5, 2025 · News and Press

Data presented for OXC-101 for a new indication – psoriasis

January 29, 2025 · News and Press

Professor Helleday presents new data on OXC-101 for psoriasis

January 23, 2025 · News and Press

Oxcia presents OXC-201 project at the Antifibrotic Drug Development Summit

December 4, 2024 · News and Press

Sandra Ekstedt was awarded funding from Karolinska Institutet to advance lung disease research

November 26, 2024 · News and Press

Oxcia AB (publ) publishes interim report for the third quarter 2024

November 22, 2024 · News and Press

Oxcia is focusing the development of OXC-101 on hematological cancers

October 4, 2024 · News and Press

Oxcia presents OXC-201 at ICLAF 2024

September 4, 2024 · News and Press

New publications in peer-reviewed scientific journals support the potential for OXC-101 as a novel anti-cancer therapy

June 11, 2024 · News and Press

Patent approval now also secured in the US, the largest IPF market

May 17, 2024 · News and Press

Search